Our Senior Team

Our senior management team members, formerly of the Merck Frosst Center for Therapeutic Research in Montreal, have extensive knowledge of the drug discovery process. Over the course of their 14 to 25 year careers, they have gained experience working in various therapeutic areas such as inflammation, respiratory diseases, pain, osteoporosis and infectious diseases and have made key contributions to the identification of several marketed small molecule therapeutics. As such, they bring vital scientific expertise and valuable project management experience to NuChem Therapeutics.

  • Marc LeBel, President of Nuchem Therapeutics brings his vast experience from the CRO world to Nuchem as co-founder of Anapharm, a Phase I CRO which grew from 8 employees to 1200 employees with revenues of more than 150M$.

    As President and then CEO of Anapharm, Marc expanded the company from Quebec City to Trois-Rivières, Montréal, Toronto and Barcelona. He also served as executive Vice-President of PharmaNet, from 2005 to 2007, following the acquisition of Anapharm. He was also interim CEO of Warnex Inc., 2012-2013 where he led the process that led to the sale of Warnex Bioanalytical to Biotrials. He was also an active member of the following boards of Directors: Université Laval, Acasti Inc, Asmacure and Nuchem Therapeutics.

    As a movie and TV producer, Marc participated in The Legend of Sarila (2013), Snowtime (2015) (short-listed for the feature film award in animation at the Oscars), and Anna (2015).

    He is the author of 120 publications and more than 130 communications. Marc received the Excelsia 2006 from BioQuébec, the leadership prize from the Canadian Society of Pharmaceutical Sciences and the Prix des Grands Diplômés from Université Laval.

    Show more
  • Daniel brings with him 20 years of experience at the Merck Frosst Canada research center in Montreal as a synthetic chemist and project leader in preclinical drug development.

    He has experience in respiratory, inflammatory, analgesic and virology therapeutic areas. Daniel was part of the discovery team of Singulair® and Arcoxia® and numerous clinical candidates.

    In 2010, he joined the Institute for Research in Immunology and Cancer (IRIC) on the Université de Montreal campus as part of the medicinal chemistry platform involved in cancer and HCV projects. Daniel earned his BSc in chemistry and doctorate degree in synthetic organic chemistry from the Sherbrooke University followed by a two year post-doctoral study at Stanford University.

    Show more
  • Sheldon has extensive experience in the process of drug discovery and development in the therapeutic areas of osteoporosis, metabolic syndrome, inflammation and HIV infection.

    Sheldon joined NuChem Therapeutics as Principal Investigator after nine year tenure at Merck Frosst Canada in which he effectively managed chemistry teams to successfully develop pre-clinical molecules within short timelines.

    Sheldon obtained his Ph.D. degree in organic chemistry under the direction of Professor Jean Burnell at the Memorial University of Newfoundland in 1999 . He then completed his post-doctoral studies at Harvard University in the laboratories of Nobel Laureate Professor E. J. Corey.

    Show more
  • Kathryn has over 20 years’ experience in the pharmaceutical industry with a sound knowledge of the preclinical drug discovery process from target identification to lead optimization.

    Prior to joining NuChem Therapeutics, Kathryn was Senior Research Associate (Biology)  at Merck Frosst Canada in Montreal. 

    She has acquired broad expertise in protein chemistry including enzymology, mechanism of action studies and assay development for enzymes and receptors from moderate to high throughput screening in various therapeutic targets including respiratory, inflammation, diabetes, obesity and infectious diseases. 

    She has over 40 publications in peer-reviewed journals.  Kathryn received her BSc in chemistry from the University of Waterloo and her MSc from the University of Alberta.

    Show more
  • John joined NuChem Therapeutics in 2014 and has over 10 years’ experience in the pharmaceutical industry with focus in the areas of epigenetics, GPCRs and peptide design.

    John joined the pre-clinical research division at MethylGene in 2005 where he was part of the team that developed the HDACi clinical candidate FRM-334 for the treatment of neurodegenerative disorders. He then moved to Tranzyme Pharma in 2010 where he gained experience in the preparation of large combinatorial libraries of cyclic peptides to target metabolic disease.

    John obtained his Ph.D. degree in synthetic organic chemistry under the direction of Professor Mark Lautens at the University of Toronto in 2003. He then completed his post-doctoral studies at the University of Pittsburgh studying natural product synthesis with Professor Dennis Curran.

    Show more
  • Marc has extensive experience in business development especially in the chemistry CRO industry. His background as a PhD chemist and experience in biopharma and high-tech make him invaluable in meeting the client’s need.

    Previously to joining Nuchem in 2014, Marc was Director of Sales and Business Development for PCAS, a custom chemistry manufacturing company and Vice President, Business Development of the Canadian division of Santai Labs, a large chemistry CRO company.

    Marc obtained his BSc, MSc and PhD degree in organic chemistry from the University of Montreal. He has various business certificates including the Executive Education, Leadership and Strategy in Pharmaceuticals and Biotech from the Harvard Business School.

    Show more
  • Lynda joined Nuchem May 2019 and has worked with several pharmaceutical CROs in the Montreal area as a finance director.

    She is a registered CPA and formerly a manager at Ernst and Young.

    Show more